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Introduction 
Systemic Lupus Erythematosus (SLE) is an autoim-
mune disease that targeted cytoplasm and nucleous 
of body cells. It causes wide manifestations from 
the most outer organ to the internal organs. Organ 
damages may varies, from mild to severe.1,2 About 
5,000,000 people around the world are affected by 
SLE. United Kingdom reported the prevalence of 
97 cases per 100,000 people in 2012.1 
Signs and symptoms of SLE can be varied. 
Genetic is predisposition factor which plays role 
in SLE pathogenesis.6 Asian reported more severe 
clinical manifestations and higher mortality rate 
compared to the American and European. SLE can 
be found in all groups age and both male and fe-
male, but it is more common found in females dur-
ing their fertile period. 1, 3-5A study by Kaplan MJ in 
2011 and Denny MF in 2010 stated that abnormal 
immune cells such as monocytes, macrophages, 
dendritic cells and others innate system compo-
nents are found in SLE patients. Involvement of 
IFN-α initiate the development of the flares’ signs 
and symptoms in SLE.7-11 
SLE is also known as “the great imitator where 
the presence of those manifestations may be not 
specific. Manifestations, such as fever, malaise, ar-
thralgia and headache are frequently found in SLE 
patients. Those symptoms are also found in others 
autoimmune diseases and hormone abnormali-
ties.12,13 In 1982, American College of Rheuma-
tology (ACR) publised criterias used to diagnosis 
SLE based on signs and symptoms detected in SLE 
patients.8,14 Many organ systems can be affected by 
SLE, included mucocutaneous, renal, cardiovas-
cular, gastrointestinal, pulmonary and hematog-
enous. From all above, the most frequent clinical 
manifestation found in SLE patients is cutaneous 
involvement, which explained the reason why SLE 
originally described as a dermatological disease. 
Further, four of eleven diagnostic criteria of SLE in 
revised ACR criteria are skin lesions.7, 13, 15, 16
Skin is the most outer organ and also the larg-
est organ of the body. It play role as body defense 
mechanism by acting as a barrier between the inner 
body and the environment.17 Disruption of the skin, 
such in SLE patients, can affect its normal function, 
thus lead to secondary infection.18 
Abstract
Background: Systemic Lupus Erythematosus (SLE) is 
an autoimmune systemic disease which symptoms in-
duced by Ultraviolet rays exposure. It commonly affects 
women and causes wide range of symptoms. One of 
the organs affected is mucocutaneous. Our study aims 
to determine mucocutaneous manifestations of SLE 
patients in Rheumatology Outpatient Clinic in Dr.Hasan 
Sadikin General Hospital, Bandung. 
Methods: A descriptive study with prospective cross-
sectional design conducted. Data were obtained by 
interviewing SLE patients as primary data and access-
ing medical record as secondary data. Ninety-six SLE 
patients met the inclusion and exclusion criteria were 
included. 
Results: From ninety-six subjects, 94.8% subjects are 
working indoors. Mucocutaneous manifestation were 
found in most patients. Based on American College of 
Rheumatology (ACR) criteria, we found mucocutane-
ous manifestations, such as: oral ulcers in 67 patients 
(69.8%); malar rash in 63 patients (65.6%);  photo-
sensitivity rash in 51 patients (53.1%), and discoid 
rash erythematous in 21 patients (21.9%). Specific LE 
cutanoeus manifestation based on Gilliam classifica-
tion were found in our study subjects, such as papulo-
squamous/ psoriasisform (19.5%) , morbilliform (17.7%), 
vesicobullous annular SCLE (13.5%), annular SCLE 
(6.3%), and TEN-like LE (1%). Non-specific LE cutaneous 
manifestations based on Gilliam classification were also 
found in our study subjects, such as oral ulcers (69.8%), 
photosensitivity rash (53.1%), alopecia (86.5%), Rayn-
aud’s Phenomenon (39.6%), nail abnormalities (24.0%), 
periungual telangiectasia patients (13.5%), vasculitic 
lesions (12.5%), thrombophlebitis (44.8%), bullous lesion 
(5.2%) and erythema multiforme (5.2%). 
Conclusion: Mucocutaneous manifestations in SLE 
patients based on ACR criteria found most in this study 
is oral ulcers. Based on Gilliam classification specific LE 
cutanoeus manifestation was not found in all SLE pa-
tients, while non-specific LE mucocutaneous manifesta-
tions mostly found is alopecia.
Keywords: American College of Rheumatology (ACR) 
criteria, Gilliam classification, Mucocutaneous manifes-
tations, Systemic Lupus Erythematosus
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Based on skin lesions characteristics, the manifestation 
of SLE in skin can be classified into 2 categories: specific 
and non-specific. Specific skin lesion is directly showed 
the specific characteristic of skin manifestations of SLE 
and severity of ilness, whereas non-specific skin lesion 
shows the progression of disease.19-21 Specific skin lesions 
are divided into acute cutaneous lesion, subacute cutaneous 
lesion and chronic cutaneous lesion. Acute cutaneous lesion 
is normally widespread and localized. Subacute cutaneous 
lesion consists of papulosquamous lesion and annular lesion. 
Chronic cutaneous lesion comprised thick and red, scaly 
patches. Nonspecific skin lesion is characterized by several 
manifestations such as photosensitivity, mucosal ulceration 
and alopecia. 20-22 
By its nature, West Java especially Bandung geographical 
location, received high exposure of sunlight can become the 
predisposing factor for the development of SLE manifestation. 
There have not been any study about mucocutaneous 
manifestation of SLE patients in Bandung. The objective of 
this study is to configure the manifestations of mucocutaneous 
in SLE patients in Rheumatology Outpatient Clinic in RSUP 
Dr. Hasan Sadikin (RSHS), Bandung. 
Method
We used a descriptive, prospective cross-sectional design. 
Data were attempted from SLE patients who came to 
Rheumatology Outpatient Clinic in RSHS from September 
2016 to November 2016. It is consisted of primary and 
secondary data. Primary data is the data which obtained 
from direct interviews. Secondary data is the data obtained 
from medical record, it was used to recheck the accuracy and 
precision of the interviews.
For sampling method, we used convenience sampling 
methods. The minimal sample’s number for this study is 96 
patients. The inclusion criteria were: 15 years old or more, 
diagnosed as SLE patients based on American College of 
Rheumatology’s (ACR) criteria, attend to the Rheumatology 
Outpatient Clinic during the interview period. The exclusion 
criteria was patient who rejects to be interviewed. Patients 
met those criteria would be interviewed using a questionnaire. 
Data collected included demographic characteristics such 
as gender, age and occupation; and mucocutaneous findings 
which enlisted in ACR criteria and Gilliam classification. 
After the interview, we crosschecked the information obtained 
with their medical record.  
All data were inserted to Microsoft Office Excel and 
analyzed by using descriptive analysis within Statistical 
Packages for Social Sciences (SPSS) version 20. The study has 
been approved by Health Research Ethics Committee, Faculty 
of medicine, Padjadjaran University and with permission from 
board of director of RSHS.
Result
Ninety-six SLE patients were included to our study. The 
distribution data of SLE patients that comprised in this study 
based on the listed characteristics can be observed in following 
table.
Table 1 Demographic characteristics of SLE patients interviewed
Characteristics Frequency (n=96)
N (%)
Gender
Male 3 (3.1%)
Female 93 (96.9%)
Age
15-24 23 (24.0%)
25-34 29 (30.2%)
35-44 29 (30.2)
45-54 14 (14.6%)
≥55 1 (1.0%)
Occupation
    Indoor 91 (94.8%)
    Outdoor 5 (5.2%)
Most subjects were female (96.9%). Patients’ age were 
categorized into 5 age groups with 10 years of time interval. 
Patients was frequently found in group age of 25-34 and 35-44 
years old with 29 subjects (30.2%) in each group. The study 
noted that 91 samples (94.8%) of our study worked indoor.
SLE patients normally experienced several mucocutanoe-
us manifestations at a time. Table 2 and Table 3 below show 
the mucocutanoeus manifestation based on ACR revised crite-
ria and Gilliam LE-Cutaneous classification.
Table 2. Revised ACR Criteria Mucocutaneous Manifestation 
Characteristic Frequency (%)
Malar Rash 63 (65.6%)
Discoid Rash Erythematous 21 (21.9%)
Photosensitivity Rash 51 (53.1%)
Oral Ulcers 67 (69.8%)
Table 3. Gilliam Classification Mucocutaneous Manifestation
Characteristics Frequency (%)
Specific
  Morbilliform 17 (17.7%)
  Papulosquamous/psoriasiform 19 (19.8%)
  Vesiculobullous annular SCLE 13 (13.5%)
Toxic epidermal necrolysis–like LE 1 (1%)
  Annular SCLE 6 (6.3%)
Non specific
  Photosensitivity Rash 51 (53.1%)
Alopecia 83 (86.5%)
Oral Ulcers 67 (69.8%)
  Bullous lesions 5 (5.2%)
Raynaud’s phenomenon 38 (39.6%)
Vasculitis lesions 12 (12.5%)
Erythema multiforme 5 (5.2%)
Periungual telangiectasia 13 (13.5%)
Nail abnormalities 23 (24%)
  Thrombophlebitis 43 (44.8%)
 
Original Article
19Indonesian Journal of Rheumatology 2017; Vol 9 No.1
Based on Revised ACR criteria, the most frequent 
mucocutaneous manifestation found are oral ulcers, accounted 
for 69.8% of all subjects. Based on the Gilliam Classification, 
the most common LE-specific mucocutaneous manifestations 
is papulosquamous/ psoriasiform 19.8%, and the least common 
found is toxic epidemal necrolysis-like LE 1%. As for LE non-
specific mucocutaneous manifestations, the majorly cutaneous 
manifestatsion found is alopecia 86.5%,  and the least found 
are bullous lesion and erythema multiforme manifestation 
which accounted for 5.2%, respectively.
Discussion
Most subjects are female, which ratio female to male is 31:1. 
As a comparison, study by Saigal et al conducted in Western 
India, also found higher ratio of SLE in female than in male, 
with ratio 11:1; and study by Budhoo et al in South African 
found 91.2% female from 408 samples. Saigal et al, Budhoo 
et al and this study enhanced the theory that SLE affects 
mostly on female.15, 23 Most SLE patients were found in group 
age of 25-34 years old and 35-44 years old. Study by Jakes et 
al and Bhaskar et al, showed mean age found for SLE patients 
is 25.7-34.5 years old and 21-30 years old, where it is a close 
meet to the most age group found in this study.3, 24 William 
stated that age from 15 to 44 years old is a fertile period for a 
female.25 Therefore, it can be concluded that SLE mostly can 
affect female who is in childbearing age.
We found that more patients worked indoor than outdoor. 
Exposure to ultraviolet (UV) rays is one of the triggering 
factors of flares in SLE patients.7, 8 Based on Mak, et al study, 
exposure of UV rays especially UV-B is actually a dose depend. 
SLE patients that exposed to higher UV ray would experience 
larger necrosis of the keratinocytes and have higher degree of 
inflammation.26 In our study, eventhough most SLE patients 
worked indoor, to prevent the exposure of UV light, but most 
of them still showed mucocutaneous manifestastions. Factors 
that affects these manifestations should further be assessed. 
Based on table 2, the mucocutaneous manifestations 
enlisted in American College of Rheumatology’s criteria 
found most in this study is oral ulcers, followed by malar 
rash. It is rather different with Saigal, et al study, which 
noted that in Western India photosensitivity rash is the most 
common mucocutaneous manifestation, while in Bhaskar, et 
al study which held in Assam, Northeastern India found that 
oral ulcers is the common mucocutaneous manifestation.15, 
24 We sugested that the differences may be happened due 
to the difference level of disease activity of SLE when the 
study held. Unfortunately we did not analyze the corellation 
between SLE disease activity and the frequent mucocutaneous 
manifestations.
In the Gilliam classification comprises, mucocutaneous 
lesion is classified as specific and non-specific mucocutanous 
manifestations. It can be seen that both specific and nonspecific 
mucocutanous manifestations are found in SLE patients who 
attended our study. Yet, subject in our study experienced 
more non-specific mucocutaneous manifestations rather than 
the specific ones. Dubois mentioned that it is common that 
nonspecific mucocutaneous manifestation developed more in 
SLE patients.21 Increase in SLE non-specific mucocutaneous 
lesion is the indication of higher disease activity.27
Among non-specific SLE mucocuteneous manifestations, 
alopecia is the most common non-specific SLE mucocuteneous 
manifestations (86.5%). It is consistent with Kole, et al study 
which also found 86.67% SLE patients developed non-scarring 
alopecia manifestations. But, study by Bhaskar, et al. only 
found 52.63% of the total patients had alopecia.24, 27 Erythema 
multiforme and bullous lesion are the least manifestations 
in this study with rate 5.2% respectively. Bhaskar, et al. and 
Kole, et al. studies found erythema multiforme in 18.42% and 
6.67% patients respectively; and bullous lesions in 7.89% 
and 10% of SLE patients respectively.24, 27 These contrasts 
might be caused by the differences patients’ lifestyles and the 
severity of illness.
Papulosquamous/psoriasiform is the most frequent 
specific SLE mucocuteneous lesions found (19.8%) in this 
study. Kuhn, et al. stated that papulosquamous/psoriasiform 
is a subacute lesion. Patients with subacute lesions may have 
either papulosquamous/psoriasiform or annular lesions. But, 
only few will have both.28 In our study, only 6.3% patients had 
annular SCLE lesions. The discrepancy might occurred due 
to the difference degree of disease severity in patients. The 
lowest specific SLE mucocuteneous manifestations found in 
this study was toxic epidermal necrolysis–like LE with rate 
only 1%. Kole, et al. mentioned that there was a case of toxic 
epidermal necrolysis–like LE occurred in a patient after few 
series of relapse.27 Kuhn stated that this kind of lesion can be 
occurred with almost same properties as drug eruption case. 
28 Only small number of patient found with toxic epidermal 
necrolysis–like LE, since it is a fast-react mucocutaneous 
manifestation.29
Throughout the study, we realized several limitations. The 
researcher aware that time limitation is one of the concerns, 
even though we reached the minimal samples, but for the 
feasibility of time, we could only used convenience sampling 
methods which has lower confidence value than the systematic 
random sampling methods. We also had minimalized the recall 
errors by referring our primary data to patients’ medical record. 
However, not all data were recorded in the medical records or 
the medical records were not available due to transferred to 
other outpatient clinics during the data collection.
Conclusion
Characteristic of SLE patients with mucocutaneous 
manifestations based on revised ACR criteria, arranged from 
most frequent, was oral ulcers, malar rash, photosensitivity 
rash and discoid rash erythematous. Non-specific SLE 
mucocuteneous manifestations were found more frequent 
compared to specific SLE mucocuteneous manifestations. The 
common manifestation of non-specific SLE mucocuteneous 
manifestation is alopecia. Several recommendations to 
improve our study is improving medical records management 
system in RSUP Dr. Hasan Sadikin and awareness of every 
doctors and physician on data importance on every intervention 
made on patients. Further, multiple center studies for SLE 
mucocutaneous manifestation prevalence and incidence are 
needed.
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